Summary: In the Spring 2022 issue of the Harvard Medicine magazine, Allison Eck weaves through the challenges of Harvard’s history with psychedelics to explore the current progress of interdisciplinary psychedelic research at Harvard and beyond.
“Within the next two years, scientists and advocates are likely to succeed in securing FDA approval of MDMA for clinical use,” explains Eck. “Such a milestone would be due in large part to the efforts of MAPS, the Multidisciplinary Association for Psychedelic Studies, founded in 1986.”